Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (“Zealand”) is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under licence collaborations with Sanofi, Boehringer Ingelheim and Helsinn, and a pipeline of proprietary product candidates which primarily target specialty diseases with significant unmet needs.
The company’s first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed as Lyxumia® outside the United States and approved as Adlyxin™ in the United States. Lixisenatide has been developed in a fixed-ratio combination with basal insulin glargine (Lantus®) and is approved as Soliqua™ 100/33 in the United States, and in Europe a CHMP positive opinion recommendation was given on 11 November. Suliqua™ is the brand name in Europe.
Zealand’s proprietary pipeline includes: Dasiglucagon* (ZP4207) (single-dose rescue treatment) for acute, severe hypoglycaemia (Phase II); Glepaglutide* (ZP1848) for short bowel syndrome (Phase II); Dasiglucagon* (ZP4207) (multiple-dose version) intended for use in a dual-hormone artificial pancreas system for better hypoglycaemia control and diabetes management (Phase II); and other earlier stage clinical and preclinical peptide therapeutics.
- Dasiglucagon and glepaglutide are proposed International Nonproprietary Names (pINN).
The company is based in Copenhagen (Glostrup), Denmark.
Zealand has ~110 employees of which 80% work in research and development.
Follow us on Twitter: @ZealandPharma
Follow us on LinkedIn